Experience
Valeant Pharmaceuticals North America, LLC
Actavis, Inc.
Secured a permanent injunction against generic defendant on behalf of Valeant in Hatch-Waxman patent infringement litigation concerning an ANDA for generic versions of Carac®.
Valeant Pharmaceuticals North America, LLC v. Actavis, Inc., 2:16-cv-04344, D.N.J., Judges Linares, Dickson
Finnegan secures 10 years of patent protection for Relistor®
Valeant; Salix; Progenics
Valeant Pharmaceuticals NA, LLC v. Zydus Pharmaceuticals, Inc.
Valeant Pharmaceuticals NA, LLC
Valeant Pharmaceuticals Int’l, Inc. v. Mylan Pharmaceuticals, Inc.
Valeant; Salix; Progenics
Dow Pharmaceutical Sciences, Inc. v. Actavis, Inc.
Dow Pharmaceutical Sciences, Inc.
BTG Inc., Ltd v. Actavis Labs FL Inc.; Amneal Pharms LLC
BTG Inc., Ltd.
Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc.
Dow Pharmaceutical Sciences, Inc.; Valeant
Valeant Pharm. N. Am. LLC and Kaken Pharm. Co. Ltd. v. Zydus Pharm. (USA) Inc.
Kaken Pharmaceutical Co., Ltd.
Uniloc USA, Inc. et al v. Tencent America, LLC
Tencent America LLC
Dr. Systems Inc. v. Philips North America LLC
Philips North America LLC
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.